T9G — Vidac Pharma Holding Balance Sheet
0.000.00%
- €26.95m
- €27.56m
Annual balance sheet for Vidac Pharma Holding, fiscal year end - December 31st, GBP millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | 0.123 | 0.034 | 0.06 | 0.44 |
| Net Total Accounts Receivable | ||||
| Net Total Receivables | 0.037 | 0.008 | 0.054 | 0.024 |
| Prepaid Expenses | ||||
| Total Current Assets | 0.16 | 0.042 | 0.116 | 0.464 |
| Net Property, Plant And Equipment | 0.005 | 0.005 | 0.003 | 0.003 |
| Other Long Term Assets | ||||
| Total Assets | 0.172 | 0.047 | 0.119 | 0.467 |
| Accounts Payable | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Current Liabilities | 0.283 | 0.795 | 0.875 | 1.12 |
| Long Term Debt | ||||
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Liabilities | 0.283 | 0.795 | 0.875 | 1.12 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Other Equity | ||||
| Total Equity | -0.111 | -0.748 | -0.756 | -0.65 |
| Total Liabilities & Shareholders' Equity | 0.172 | 0.047 | 0.119 | 0.467 |
| Total Common Shares Outstanding |